Taking It Personally
March 07, 2014 – Laura Beil
Advocacy in Action
March 08, 2014 – Jane Hill
Can a Pill Prevent Cancer?
March 08, 2014 – Erik Ness
New Requirements for Patients and Survivors Needs
March 08, 2014 – Katy Human
How Survivors Can Take Action
March 08, 2014
Promises to Keep
March 06, 2014 – Tracy Stewart
Aiming to Improve Quality of Cancer Care
March 06, 2014 – Shelley Fuld Nasso
Confirmation of Lycopene's Benefits Remains Elusive
March 06, 2014 – Deborah Tolmach Sugerman
Taking Immune Action Against Lung Cancer
March 08, 2014 – Heather L. Van Epps, PhD
Pipeline
March 08, 2014 – Lindsay Ray
Preserving Security with Electronic Health Portals
March 06, 2014 – Charlotte Huff
The "To Do" List to Pass On to Well-Meaning Friends
March 08, 2014 – Don Vaughan
Choosing Quality Care
March 08, 2014 – Len Lichtenfeld, MD
Mobile App Delivers Helpful Tips to Minimize Side Effects
March 08, 2014
Legislations Could Benefit Family Caregivers
March 08, 2014 – Lena Huang
Exercise Improves Joint Pain Associated with Aromatase Inhibitors
March 08, 2014 – Jon Garinn
Moving Beyond Cancer to Wellness
March 08, 2014
Breast Cancer Prevention Study Focuses on Anti-Hormone Therapy
March 08, 2014 – Jon Garinn
Correspondent Amy Robach Receives Treatment
February 28, 2014 – Lindsay Ray
No Link Between Fertility Treatment and Overall Risk of Childhood Cancer
March 07, 2014 – Katherine Lagomarsino
Alzheimer's Disease and Cancer
March 06, 2014 – Sonya Collins
Research Updates
February 28, 2014 – Elizabeth Whittington
Genetics Leading the Way in Lung Cancer Treatment
March 05, 2014 – Debu Tripathy, MD
Letters From Readers
March 08, 2014
For Many, Caregiving Leads to Advocacy
March 07, 2014 – Jane Hill
Calming Chronic Inflammation
March 07, 2014 – Erik Ness
Making the Most Out of Your Patient Portal
March 07, 2014 – Charlotte Huff
Disclosing a Cancer Diagnosis Takes Time and Tact
March 05, 2014 – Don Vaughan
National Guidelines Aim to Make Life Better After Cancer
March 07, 2014 – Katy Human
Research Reveals New Frontiers in Lung Cancer
March 06, 2014 – Heather L. Van Epps, PhD
Biomarkers Help Patients Make Better Medical Decisions
March 06, 2014 – Laura Beil
Taking It Personally
March 07, 2014 – Laura Beil
Advocacy in Action
March 08, 2014 – Jane Hill
Can a Pill Prevent Cancer?
March 08, 2014 – Erik Ness
New Requirements for Patients and Survivors Needs
March 08, 2014 – Katy Human
How Survivors Can Take Action
March 08, 2014
Promises to Keep
March 06, 2014 – Tracy Stewart
Aiming to Improve Quality of Cancer Care
March 06, 2014 – Shelley Fuld Nasso
Confirmation of Lycopene's Benefits Remains Elusive
March 06, 2014 – Deborah Tolmach Sugerman
Taking Immune Action Against Lung Cancer
March 08, 2014 – Heather L. Van Epps, PhD
Pipeline
March 08, 2014 – Lindsay Ray
Preserving Security with Electronic Health Portals
March 06, 2014 – Charlotte Huff
The "To Do" List to Pass On to Well-Meaning Friends
March 08, 2014 – Don Vaughan
Choosing Quality Care
March 08, 2014 – Len Lichtenfeld, MD
Mobile App Delivers Helpful Tips to Minimize Side Effects
March 08, 2014
Legislations Could Benefit Family Caregivers
March 08, 2014 – Lena Huang
Exercise Improves Joint Pain Associated with Aromatase Inhibitors
March 08, 2014 – Jon Garinn
Moving Beyond Cancer to Wellness
March 08, 2014
Breast Cancer Prevention Study Focuses on Anti-Hormone Therapy
March 08, 2014 – Jon Garinn
Correspondent Amy Robach Receives Treatment
February 28, 2014 – Lindsay Ray
No Link Between Fertility Treatment and Overall Risk of Childhood Cancer
March 07, 2014 – Katherine Lagomarsino
Alzheimer's Disease and Cancer
March 06, 2014 – Sonya Collins
Currently Viewing
Research Updates
February 28, 2014 – Elizabeth Whittington
Letters From Readers
March 08, 2014
For Many, Caregiving Leads to Advocacy
March 07, 2014 – Jane Hill
Calming Chronic Inflammation
March 07, 2014 – Erik Ness
Making the Most Out of Your Patient Portal
March 07, 2014 – Charlotte Huff
Disclosing a Cancer Diagnosis Takes Time and Tact
March 05, 2014 – Don Vaughan
National Guidelines Aim to Make Life Better After Cancer
March 07, 2014 – Katy Human
Research Reveals New Frontiers in Lung Cancer
March 06, 2014 – Heather L. Van Epps, PhD
Biomarkers Help Patients Make Better Medical Decisions
March 06, 2014 – Laura Beil
The Priority List: A Teacher's Final Quest to Discover Life's Greatest Lessons
March 08, 2014
What to Do When Radiation Causes Skin Damage
March 07, 2014 – Lacey Meyer

Research Updates

Updates from ASCO's Genitourinary Cancers Symposium.

BY Elizabeth Whittington
PUBLISHED February 28, 2014

This year marks the 10th anniversary of the oncology meeting devoted to genitourinary cancers, which includes prostate, kidney and bladder. The American Society of Clinical Oncology’s Genitourinary Cancers Symposium, held Jan. 30 to Feb. 1 in San Francisco, presented several studies that may impact clinical practice and future research in genitourinary cancers. Here are a few notable findings.

Men with advanced prostate cancer are typically given hormone therapy (androgen deprivation) until the disease progresses, at which point the next option is usually chemotherapy. Because prostate cancer is generally a slow-growing disease, delaying time to chemotherapy has been one goal in treatment. Xtandi (enzalutamide), an oral drug that blocks the androgen receptor, was approved in 2012 after it was shown to extend survival for men whose metastatic, castration-resistant prostate cancer had progressed on docetaxel.

The results of the phase 3 PREVAIL study showed that when men were given Xtandi before chemotherapy, the drug delayed disease progression, improved survival, delayed time to chemotherapy and improved quality of life.

The trial randomized more than 1,700 men who had few or no symptoms of their advanced prostate cancer to receive Xtandi or a placebo. Overall, Xtandi delayed the time to chemotherapy by about 17 months. Side effects were minimal and similar in both groups of patients and included fatigue, back pain, constipation and hypertension.

The interim results clearly showed the benefit of Xtandi, which led an independent data-monitoring committee to recommend that the trial be stopped early and patients receiving placebo be offered Xtandi.

“I think it’s safe to say that enzalutamide provided a significant clinical benefit to patients with metastatic castration-resistant prostate cancer,” said Tomasz Beer, lead author of the study, as he concluded the presentation.

After disease progression, participants in the trial received other therapies, including docetaxel, Zytiga (abiraterone), Jevtana (cabazitaxel), Provenge (sipuleucel-T) and Xtandi, many of which were approved in the past few years—a testament to the advances in prostate cancer treatment.

High blood pressure medications called angiotensin system inhibitors (ASIs) impact blood flow to a tumor, which could make them an ideal addition to cancer treatment. Researchers looked at data from several studies that included participants with metastatic kidney cancer who received ASIs within the first 30 days of a clinical trial. Those trials were testing a variety of anticancer drugs, including Avastin (bevacizumab), Sutent (sunitinib), Torisel (temsirolimus) and interferon alfa. (You can view the results here.)

Retrospective data showed participants who took blood pressure medication along with their anticancer drug had longer survival and delayed tumor progression. Participants who received an antiangiogenic drug, such as Avastin (a drug that blocks blood flow to a tumor), along with an ASI experienced even more significant results, with an improvement in survival time of nine months compared with participants not receiving an ASI. Study subjects receiving an ASI and an mTOR inhibitor or interferon alfa did not experience a significant improvement.

Researchers are not encouraging the use of ASIs in nonhypertensive patients with advanced kidney cancer, but patients who have high blood pressure and receive antiangiogenic cancer treatment should certainly consider ASIs.

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Kidney Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In